Genetic Toxicology Screens

There is a demand for accurate toxicity screening during lead optimization.  MBR’s microAmes screen offers the industry’s first and only mutagencity screen that fully predicts the gold standard GLP regulatory Ames Test – a claim no other company can make.  The microAmes can screen compounds in less time and using less material than the traditional Ames test.

MBR’s microAmes uses only 5-10 mg of test article while mimicking the regulatory Ames format. Based on years of experience with the microAmes screen, we ensure results are delivered in two weeks or less from receipt of compound.  We also offer structure-toxicity interpretation and provide strategic advice to help companies act quickly on their drug candidates.